Title : Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.

Pub. Date : 2022 Jul 5

PMID : 35447433






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The C797S mutation in EGFR is a leading mechanism of clinically acquired resistance against osimertinib for non-small cell lung cancer (NSCLC). osimertinib epidermal growth factor receptor Mus musculus